80,758 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. bought a new stake in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 80,758 shares of the medical research company’s stock, valued at approximately $5,979,000. Edwards Lifesciences accounts for approximately 0.3% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 22nd biggest holding.

A number of other large investors also recently added to or reduced their stakes in EW. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $555,939,000. Assenagon Asset Management S.A. raised its stake in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at $213,844,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.46 on Friday. The firm has a market cap of $41.42 billion, a P/E ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The business’s 50-day moving average price is $71.42 and its 200 day moving average price is $70.37. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,303 shares of company stock worth $3,715,776. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EW shares. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.